Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases
Open accessAbstract
Members of the nuclear receptor (NR) superfamily of ligand-activated transcription factors are players of substantial relevance in the regulation of hepatic gene expression. NRs direct normal physiology and metabolism, adaptations to liver disease, and responses to inflammation and toxins.They also contribute to the regenerative response. In this review, we summarize currently available experimental and clinical data, focusing on the role of NRs in cholestasis and nonalcoholic fatty liver disease (NAFLD). We also highlight the potential of NRs as targets for safe and effective therapeutic interventions.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Natural ligands that interact with and regulate nuclear receptor activity are typically small lipophilic molecules, such as hormones, bile acids, oxysterols, fatty acids, vitamins, cholesterol, and exogenous substances including toxins.
“The natural ligands that interact and regulate NR-activity are typically small lipophilic molecules, such as hormones, bile acids, oxysterols, fatty acids, vitamins, cholesterol, and exogenous substances, including toxins.[32]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · see citing works
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · see citing works
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830 · see citing works
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436 · see citing works
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,228 · see citing works
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Utzschneider, K. M., & Kahn, S. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0587 · Cited by 858 · see citing works
Integration of metabolism and inflammation by lipid-activated nuclear receptors
Bensinger, S. J., & Tontonoz, P. (2008) · Nature · doi:10.1038/nature07202 · Cited by 813 · see citing works
Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W. (2008) · Hepatology · doi:10.1002/hep.22519 · Cited by 639 · see citing works
Insulin resistance, inflammation, and non-alcoholic fatty liver disease
Tilg, H., & Moschen, A. R. (2008) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.08.005 · Cited by 470 · see citing works
Adipokines in liver diseases #
Marra, F., & Bertolani, C. (2009) · Hepatology · doi:10.1002/hep.23046 · Cited by 470 · see citing works
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Anderson, N., & Borlak, J. T. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.00001 · Cited by 384 · see citing works
Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis
Alkhouri, N., Górnicka, A., Berk, M. P., Thapaliya, S., Dixon, L. J., Kashyap, S. R., Schauer, P. R., & Feldstein, A. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074252 · Cited by 368 · see citing works
Geier, A., Wagner, M., Dietrich, C. G., & Trauner, M. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 313 · see citing works
Trauner, M., Arrese, M. A., & Wagner, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.10.007 · Cited by 291 · see citing works
Self-citationNew molecular insights into the mechanisms of cholestasis.
Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 270 · see citing works
Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease
Dong, B., Saha, P., Huang, W., Chen, W., Abu-Elheiga, L. A., Wakil, S. J., Stevens, R. D., Ilkayeva, O., Newgard, C. B., Chan, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909731106 · Cited by 262 · see citing works
Mechanisms of Disease: mechanisms and clinical implications of cholestasis in sepsis
Geier, A., Fickert, P., & Trauner, M. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0602 · Cited by 227 · see citing works
Physiology and pathophysiology of liver inflammation, damage and repair.
Ramadori, G. P., Moriconi, F., Malik, I. A., & Dudás, J. (2008) · PubMed · Cited by 183 · see citing works
Nuclear receptor regulation of hepatic function
Karpen, S. J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00129-0 · Cited by 169 · see citing works
Self-citationBile acid transporters in health and disease
Kosters, A., & Karpen, S. J. (2008) · Xenobiotica · doi:10.1080/00498250802040584 · Cited by 160 · see citing works
Self-citationNuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146 · see citing works
Ghose, R., Zimmerman, T. L., Thevananther, S., & Karpen, S. J. (2004) · Nuclear Receptor · doi:10.1186/1478-1336-2-4 · Cited by 134 · see citing works
Self-citationInsulin resistance and steatosis in humans
Capeau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74600-7 · Cited by 130 · see citing works
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
Ali, R., & Cusi, K. J. (2009) · Annals of Medicine · doi:10.1080/07853890802552437 · Cited by 110 · see citing works
George, J., & Liddle, C. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700110z · Cited by 80 · see citing works
Defining therapeutic targets for liver fibrosis: Exploiting the biology of inflammation and repair
Iredale, J. P. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.011 · Cited by 80 · see citing works
c‐Jun N‐terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease
Kodama, Y., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22710 · Cited by 73 · see citing works
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
Cariou, B. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74605-6 · Cited by 59 · see citing works
Donner, M. G., Warskulat, U., Saha, N., & Häussinger, D. (2004) · Biological Chemistry · doi:10.1515/bc.2004.029 · Cited by 58 · see citing works
Wagner, M., Zollner, G., & Trauner, M. (2008) · Hepatology · doi:10.1002/hep.22668 · Cited by 40 · see citing works
Hepatocyte nuclear factor-4α is a central transactivator of the mouse Ntcp gene
Geier, A., Martin, I. V., Dietrich, C. G., Balasubramaniyan, N., Strauch, S., Suchy, F. J., Gartung, C., Trautwein, C., & Ananthanarayanan, M. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00012.2008 · Cited by 39 · see citing works
The new therapeutic frontier--nuclear receptors and the liver
Karpen, S. J., & Trauner, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.002 · Cited by 29 · see citing works
Self-citationNuclear factor- B inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy
Marra, F. (2008) · Gut · doi:10.1136/gut.2007.141986 · Cited by 26 · see citing works
Xenobiotic-Sensing Nuclear Receptors CAR and PXR as Drug Targets in Cholestatic Liver Disease
Kakizaki, S., Takizawa, D., Tojima, H., Yamazaki, Y., & Mori, M. (2009) · Current Drug Targets · doi:10.2174/138945009789735174 · Cited by 24 · see citing works
Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis
Mulder, J. (2009) · Frontiers in bioscience · doi:10.2741/3400 · Cited by 23 · see citing works
Dasarathy, S. (2008) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607108324584 · Cited by 23 · see citing works
Elfaki, D., Bjornsson, E. S., & Lindor, K. D. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04104.x · Cited by 14 · see citing works
Look Who's Talking: Nuclear Receptors in the Liver and Gastrointestinal Tract
Downes, M., & Liddle, C. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.02.006 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [31]Bensinger SJ Tontonoz P Integration of metabolism and inflammation by lipid-activated nuclear receptors Nature 454 470 7 2008 18650918
Cited by
Sorted by citations
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943 · see citing works
Self-citationRecent insights on the role of cholesterol in non-alcoholic fatty liver disease
Argüello, G., Balboa, E., Arrese, M. A., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306 · see citing works
Self-citationFree radical biology for medicine: learning from nonalcoholic fatty liver disease
Serviddio, G., Bellanti, F., & Vendemiale, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.174 · Cited by 269 · see citing works
Nuclear Receptors in Liver Disease Δ
Wagner, M., Zollner, G., & Trauner, M. (2011) · Hepatology · doi:10.1002/hep.24148 · Cited by 260 · see citing works
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 132 · see citing works
Ivashkin, V. T., Mayevskaya, M. V., Pavlov, C. S., Тихонов, И. Н., Shirokova, E. N., Buyeverov, A. O., Drapkina, O. M., Shulpekova, Y. O., Tsukanov, V. V., Mammayev, S. N., et al. (2016) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2016-26-2-24-42 · Cited by 125 · see citing works
Li, R., Xu, L., Liang, T., Li, Y., Zhang, S., & Duan, X. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.10.059 · Cited by 111 · see citing works
Fuchs, M. A. (2011) · Journal of Lipids · doi:10.1155/2012/934396 · Cited by 108 · see citing works
Mencarelli, A., Migliorati, M., Barbanti, M., Cipriani, S., Palladino, G., Distrutti, E., Renga, B., & Fiorucci, S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.022 · Cited by 103 · see citing works
Cabrera, D., Arab, J. P., & Arrese, M. A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_241 · Cited by 100 · see citing works
Self-citationNuclear receptors as therapeutic targets in liver disease: are we there yet?
Rudraiah, S., Zhang, X., & Wang, L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103209 · Cited by 87 · see citing works
Sex differences in nuclear receptor-regulated liver metabolic pathways
Rando, G., & Wahli, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.023 · Cited by 86 · see citing works
Cui, J. Y., & Klaassen, C. D. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.04.010 · Cited by 83 · see citing works
Wu, J., Wang, C., Li, S., Li, S., Wang, W., Li, J., Chi, Y., Yang, H., Kong, X., Zhou, Y., et al. (2013) · Hepatology · doi:10.1002/hep.26272 · Cited by 81 · see citing works
Gu, M., Zhao, P., Huang, J.-W., Zhao, Y., Wang, Y.-H., Li, Y., Li, Y.-F., Fan, S., Ma, Y.-M., Tong, Q., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00345 · Cited by 76 · see citing works
Ducheix, S., Montagner, A., Théodorou, V., Ferrier, L., & Guillou, H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.016 · Cited by 75 · see citing works
Long Noncoding RNA lnc-HC Regulates PPARγ-Mediated Hepatic Lipid Metabolism through miR-130b-3p
Lan, X., Wu, L., Wu, N., Chen, Q., Li, Y., Du, X., Wei, C., Feng, L., Li, Y., Osoro, E. K., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.018 · Cited by 56 · see citing works
Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling
Gu, M., Zhang, S., Zhao, Y., Huang, J., Wang, Y., Li, Y., Fan, S., Yang, L., Ji, G., Tong, Q., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.021 · Cited by 55 · see citing works
Nuclear Receptors in Nonalcoholic Fatty Liver Disease
López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, N. (2012) · Journal of Lipids · doi:10.1155/2012/139875 · Cited by 48 · see citing works
Bile Acids in Cholestasis and its Treatment
Arab, J. P., Cabrera, D., & Arrese, M. A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5497 · Cited by 47 · see citing works
Self-citationNuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45 · see citing works
Biological Functions of Thyroid Hormone in Placenta
Chen, C.-Y., Chen, C., & Lin, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024161 · Cited by 45 · see citing works
Nuclear Receptors in Acute and Chronic Cholestasis
Gonzalez‐Sanchez, E., Firrincieli, D., Housset, C., & Chignard, N. (2015) · Digestive Diseases · doi:10.1159/000371688 · Cited by 36 · see citing works
Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
Song, C., Long, X., He, J., & Huang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1081334 · Cited by 34 · see citing works
Arrese, M. A., Riquelme, A. J., & Soza, A. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31735-1 · Cited by 32 · see citing works
Self-citationYetti, H., Naito, H., Yuan, Y., Jia, X., Hayashi, Y., Tamada, H., Kitamori, K., Ikeda, K., Yamori, Y., & Nakajima, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192863 · Cited by 24 · see citing works
A network biology workflow to study transcriptomics data of the diabetic liver
Kutmon, M., Evelo, C. T., & Coort, S. L. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-971 · Cited by 24 · see citing works
Orostachys japonicus ameliorates acetaminophen-induced acute liver injury in mice
Zhou, Z., Qi, J., Zhao, J., Seo, J. H., Shin, D. G., Cha, J., Lim, C. W., Kim, J.-W., & Kim, B. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113392 · Cited by 23 · see citing works
In-depth Proteomic Characterization of Endogenous Nuclear Receptors in Mouse Liver
Liu, Q., Ding, C., Liu, W., Song, L., Liu, M., Qi, L., Fu, T., Malovannaya, A., Wang, Y., Qin, J., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.022319 · Cited by 19 · see citing works
Yang, X., Lü, M., You, L., Gen, H., Yuan, L., Tian, T., Li, C., Xu, K., Hou, J., & Lei, M. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00470-x · Cited by 18 · see citing works
Farnesoid X Receptor Agonists: What They Are and How They Might Be Used in Treating Liver Disease
Neuschwander‐Tetri, B. A. (2011) · Current Gastroenterology Reports · doi:10.1007/s11894-011-0232-6 · Cited by 18 · see citing works
Elevated Peripheral Blood Monocyte Fraction in Nonalcoholic Fatty Liver Disease
Kim, H., Chung, G. E., Park, I. Y., Choi, J. M., Hwang, S.-M., Lee, J., & Kim, D. (2011) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.223.227 · Cited by 18 · see citing works
Sun, H., Shao, W., Liu, H., & Jiang, Z. (2018) · Environmental Science and Pollution Research · doi:10.1007/s11356-018-1921-6 · Cited by 15 · see citing works
Quintero, P., & Arrese, M. A. (2013) · Hepatology · doi:10.1002/hep.26582 · Cited by 14 · see citing works
Self-citationPiccinno, M., Rizzo, A., Maselli, M. A., Derosa, M., & Sciorsci, R. L. (2014) · Theriogenology · doi:10.1016/j.theriogenology.2014.08.008 · Cited by 12 · see citing works
Obeticholic acid: expanding the therapeutic landscape of NASH
Arrese, M. A., Cabrera, D., & Francisco Barrera, M. (2015) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31286-4 · Cited by 9 · see citing works
Self-citationÖzkan, S., Aksan, A., Kurt, D. S., Kurt, A. F., Fıratlıgil, F. B., Sucu, S. T., Sucu, S., Reis, Y. A., Öztürk, B. G., & Çağlar, A. T. (2024) · American Journal of Reproductive Immunology · doi:10.1111/aji.13937 · Cited by 8 · see citing works
Pastor, C. M., Wissmeyer, M., & Millet, P. (2012) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1511 · Cited by 8 · see citing works
MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH
Wang, Y., Shen, Q.-L., Xin, Q., Sun, B., Zhang, S., Fang, Q., Shi, Y., Niu, W.-Y., Lin, J., & Li, C. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0022 · Cited by 7 · see citing works
Genetic determinants of acquired cholestasis: A systems biology approach
Sookoian, S. C. (2011) · Frontiers in bioscience · doi:10.2741/3922 · Cited by 4 · see citing works
Wang, F., Wu, Y., Xie, X., Sun, J., & Chen, W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.012 · Cited by 4 · see citing works
Contractile effect of rifaximin on bovine uterus in the presence of steroid hormone antagonists
Sciorsci, R. L., Piccinno, M., & Rizzo, A. (2018) · Theriogenology · doi:10.1016/j.theriogenology.2017.12.049 · Cited by 4 · see citing works
Stan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2628 · Cited by 3 · see citing works
Hepatocellular Carcinoma: Epidemiology and Etiology
Degli, D., Soffritti, M., Lemoine, A., Tibaldi, E., & Manservigi, M. (2012) · InTech eBooks · doi:10.5772/30709 · Cited by 2 · see citing works
Hamraev, A., & Yuldasheva, D. H. (2021) · The American Journal of Medical Sciences and Pharmaceutical Research · doi:10.37547/tajmspr/volume03issue03-11 · Cited by 1 · see citing works
Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
Gao, W., Li, Z., Chu, H., Yuan, H., Hu, L., Yao, L., Zhang, L. R., Wang, W., Lin, R., & Yang, L. (2022) · Springer eBooks · doi:10.1007/978-981-19-2615-0_6 · Cited by 1 · see citing works
Tratamiento del hígado graso no alcohólico: ¿Qué sabemos?
Pablo, J., Arab, V., Ramírez, C. C., Gran, I., Riquelme, P. A., & Arrese, J. M. (2010)
Хamrayev, A. A., & Yuldasheva, D. H. (2021) · Общество и инновации · doi:10.47689/2181-1415-vol2-iss2/s-pp399-406
Managing biological data in pathways and networks
Kutmon, M. (2015) · doi:10.26481/dis.20150122mk
Ugare, S. R., Khatib, N. A., Beerwala, F. A., Ratnakar, A., Patil, D., Patil, V. S., & Harish, D. R. (2024) · Journal of Young Pharmacists · doi:10.5530/jyp.2024.16.61
Razori, M., Hillotte, G. L., Martín, P. L., Barosso, I., Basiglio, C., Ruiz, M. L., & Roma, M. G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111393
Diversité des macrophages dans un modèle murin de stéatohépatite non alcoolique
Tran, S. (2019) · theses.fr (ABES) · doi:10.70675/22efc884z2788z43fazabc1zaeb115ea6833
- Authors
- Arrese, M., & Karpen, S. J.
- Affiliations
- Pontificia Universidad Católica de Chile (CL)
- Baylor College of Medicine (US)
- ORCID
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-03-03
- Volume
- 87
- Issue
- 4
- Pages
- 473-478
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- PMC
- PMC4120751
- OpenAlex
- W2025681009
- Cited by
- 54
- References
- 38
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 4 · 2015: 5 · 2014: 2 · 2013: 5 · 2012: 4
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK056239, DK56239)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Keywords
- nuclear receptors, cholestasis, non-alcoholic fatty liver disease, liver inflammation, hepatic gene expression, liver regeneration, therapeutic target, hepatotoxicity
- MeSH terms
- Animals, Cholestasis, Fatty Liver, Humans, Inflammation, Drug Delivery Systems, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
